MYC and neoplasm: TNBC is a malignant cancer that lacks specific therapeutic targets.6 c-Myc is a pivotal oncogenic driver in TNBC, and pharmacological inhibition of this target demonstrates anti-tumor efficacy.19,22,23 However, due to the physiological functions of c-Myc, the long-term application of its inhibitors is limited in TNBC treatment.24 Although c-Myc is overexpressed in TNBC, the underlying mechanisms remain unclear.